Puma regains China rights to Nerlynx and amends deal with Fabre

26 February 2021

Puma Biotechnology (Nasdaq: PBYI) has agreed to terminate its 2018 license agreement with China-based CANbridge Pharmaceutical, in which the latter was granted exclusive rights to develop and commercialize Nerlynx (neratinib) in Greater China, and to settle their arbitration related to the license agreement.

Simultaneous, Puma – whose shares dipped 2.7% to $10.26 by mid-morning - has agreed with privately-held French drugmaker Pierre Fabre to amend the terms of their 2019 license agreement, which grants Pierre Fabre exclusive rights to develop and commercialize Nerlynx within Europe, Turkey, Middle East and Africa, to also include Greater China, which includes mainland China, Taiwan, Hong Kong and Macau.

At the same time, CANbridge and Pierre Fabre have entered into agreements under which CANbridge will provide Pierre Fabre certain transition services in Greater China and distribute and market Nerlynx for Pierre Fabre in Hong Kong, Macau, and Taiwan until year end 2022, with an option to renew.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK